Valeant Pharmaceuticals is selling its Obagi Medical Products business to Haitong International Zhonghua Finance Acquisition Fund I for $190 million in cash.
As rumors swirled about whether or not AstraZeneca Chief Executive Officer Pascal Soriot was leaving for Israel-based Teva Pharmaceutical, investors expressed their concerns with a sell off that cost the British company $4 billion overnight.
FDA approved Janssen Biotech’s Tremfya (guselkumab) for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
San Diego-based Arena Pharmaceuticals’ shares rocketed after positive data was announced from its Phase II clinical trial of a drug for pulmonary arterial hypertension (PAH).
The world’s top medical technology companies are turning to robots to help with complex knee surgery, promising quicker procedures and better results in operations that often leave patients dissatisfied.
Novartis signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019.
Bristol-Myers Squibb announced promising interim data from its Phase III clinical trial of Opdivo 3 mg/kg compared to 10 mg/kg Yervoy in melanoma.
Investors in drugmaker AstraZeneca have taken defensive positions in the options market ahead of eagerly awaited results of a major trial of a lung cancer treatment.
Portola Pharmaceuticals announced that the U.S. Food and Drug Administration approved the potential blockbuster drug Bevyxxa (betrixaban).